Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/97886
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarikishore, Amaravadhien
dc.contributor.authorLi, Enlinen
dc.contributor.authorLee, Jia Junen
dc.contributor.authorCho, Nam-Joonen
dc.contributor.authorYoon, Ho Supen
dc.date.accessioned2015-08-25T06:43:38Zen
dc.date.accessioned2019-12-06T19:47:41Z-
dc.date.available2015-08-25T06:43:38Zen
dc.date.available2019-12-06T19:47:41Z-
dc.date.copyright2015en
dc.date.issued2015en
dc.identifier.citationHarikishore, A., Li, E., Lee, J. J., Cho, N.-J., & Yoon, H. S. (2015). Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Molecular Diversity, 19(3), 529-539.en
dc.identifier.urihttps://hdl.handle.net/10356/97886-
dc.identifier.urihttp://hdl.handle.net/10220/38515en
dc.description.abstractHepatitis C virus (HCV) infection or HCV-related liver diseases are now shown to cause more than 350,000 deaths every year. Adaptability of HCV genome to vary its composition and the existence of multiple strains makes it more difficult to combat the emergence of drug-resistant HCV infections. Among the HCV polyprotein which has both the structural and non-structural regions, the non-structural protein NS5B RNA-dependent RNA polymerase (RdRP) mainly mediates the catalytic role of RNA replication in conjunction with its viral protein machinery as well as host chaperone proteins. Lack of such RNA-dependent RNA polymerase enzyme in host had made it an attractive and hotly pursued target for drug discovery efforts. Recent drug discovery efforts targeting HCV RdRP have seen success with FDA approval for sofosbuvir as a direct-acting antiviral against HCV infection. However, variations in drug-binding sites induce drug resistance, and therefore targeting allosteric sites could delay the emergence of drug resistance. In this study, we focussed on allosteric thumb site II of the non-structural protein NS5B RNA-dependent RNA polymerase and developed a five-feature pharmacophore hypothesis/model which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Further, the Güner-Henry score of 0.6 suggests that the model was able to discern the active and inactive compounds and enrich the true positives during a database search. In this study, database search and molecular docking results supported by experimental HCV viral replication inhibition assays suggested ligands with best fitness to the pharmacophore model dock to the key residues involved in thumbs site II, which inhibited the HCV 1b viral replication in sub-micro-molar range. HCV nonstructural protein NS5B RNA-dependent RNA polymerase (RdRP) mediates the catalytic role of viral RNA replication. Lack of host RNA-dependent RNA polymerase enzyme had made it an attractive and hotly pursued target for drug discovery efforts. In this study, we developed a five-feature pharmacophore (3D QSAR) model for thumb site inhibitors of HCV RdRP, which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Our database search and molecular docking results suggested that the compounds 1 and 2 with best fitness to the pharmacophore model were predicted to interact with key residues involved in thumbs site II and could inhibit the HCV RdRP activity. Further, the compounds 1 and 2 potently inhibited HCV 1b viral replication in sub-micro-molar range.en
dc.language.isoenen
dc.relation.ispartofseriesMolecular diversityen
dc.rights© 2015 Springer. This is the author created version of a work that has been peer reviewed and accepted for publication by Molecular Diversity, Springer. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1007/s11030-015-9591-5].en
dc.subjectDRNTU::Science::Biological sciences::Molecular biologyen
dc.titleCombination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymeraseen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Biological Sciencesen
dc.identifier.doi10.1007/s11030-015-9591-5en
dc.description.versionAccepted versionen
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:SBS Journal Articles

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.